Neptune Technologies & Bioressources Inc  

(Public, TSE:NTB)   Watch this stock  
Find more results for NTB
-0.06 (-3.97%)
Feb 8 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.43 - 1.55
52 week 1.30 - 2.43
Open 1.53
Vol / Avg. 27,405.00/33,946.00
Mkt cap 111.54M
P/E     -
Div/yield     -
EPS -0.23
Shares 77.94M
Beta 0.93
Inst. own     -
Jan 13, 2016
Q3 2016 Neptune Technologies & Bioressources Inc Earnings Call
Jan 12, 2016
Q3 2016 Neptune Technologies & Bioressources Inc Earnings Release
Jan 8, 2016
Neptune Technologies & Bioressources Inc Acquires Biodroga Inc.
Dec 7, 2015
Preliminary Q3 2016 Neptune Technologies & Bioressources Inc Earnings Release

Key stats and ratios

Q4 (Nov '15) 2015
Net profit margin -53.04% -197.89%
Operating margin -56.44% -262.76%
EBITD margin - -251.35%
Return on average assets -13.39% -29.63%
Return on average equity -14.36% -52.86%
Employees 123 -
CDP Score - -


545 Prom du Centropolis Suite 100
+1-450-6872262 (Phone)
+1-450-6872272 (Fax)

Website links


Neptune Technologies & Bioressources Inc is a Canada-based biotechnology company. The Company is engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids (PUFAs). The Company has three operating segments: Neptune, Acasti Pharma Inc. and NeuroBioPharm Inc. The Company's Neptune segment produces and commercializes nutraceutical products. The Company's Acasti Pharma Inc. segment develops and commercializes medical food and pharmaceutical products for cardiovascular diseases. The Company's NeuroBioPharm Inc. segment develops medical food and pharmaceutical products for neurological diseases. The Company's lead product, Neptune Krill Oil (NKO), come in capsule form and serve as a dietary supplement to consumers. The Company's other nutraceutical products include Ecokrill Oil (EKO), Rimfrost Oil, Neptune Krill Aquatein ( NKA) and New Formulation Derived from NKO, which include NKO Beat, NKO Flex and NKO Focus.

Officers and directors

Pierre Fitzgibbon Chairman of the Board
Age: 60
James Stuart Hamilton President, Chief Executive Officer, Director
Mario Paradis Chief Financial Officer
Michel Timperio Senior Vice President of Sales - Global Sales
Pierre Lemieux Ph.D. Chief Operating Officer of Acasti
Jean-Daniel Belanger Corporate Secretary and Director - Corporate Affairs
Harlan W. Waksal M.D. Director
Age: 61
Valier Boivin Independent Director
Ronald Denis Independent Director
Adrian Taylor Montgomery Independent Director